Inhibition of Annexin A3 Suppresses Cell Proliferation and Aggressiveness in Colorectal Cancer

Xiao-fen Li,Wang-xiong Hu,Jie-kai Yu,Shu Zheng
DOI: https://doi.org/10.1016/j.cgh.2016.09.120
IF: 13.576
2016-01-01
Clinical Gastroenterology and Hepatology
Abstract:Annexin A3 (ANX A3) is a calcium-dependent phospholipid-binding protein, which is associated with carcinogenesis and metastasis in many cancers such as ovarian cancer, gastric cancer, et al. But its role in colorectal cancer (CRC) is unclear. We conducted this study to investigate the cellular and clinical functions of ANX A3 in CRC. The expression level of ANX A3 in CRC patients was determined by enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC) and western blotting analysis. An inhibition plasmid vector of ANX A3-small hairpin RNA (shRNA) and an ANX A3 expression plasmid vector were constructed and transfected into SW620 cells. Cell proliferation, migration, invasion and cycle were detected after transfection. Serum level of ANX A3 in CRC patients was significantly higher compared with normal controls (0.71±0.41 vs 0.36±0.35 ng/mL, p<0.0001). IHC and western blotting analysis of 19 pairs of CRC tissue and adjacent normal mucosa validated significantly over expression of ANX A3 in CRC (p<0.05). CCK-8 experiments on transfected cells showed that inhibition ANX A3 significantly suppressed cell proliferation. Transwell tests indicated that inhibition ANX A3 could significantly reduce cell migration and invasion. Flow cytometry results showed that over expression of ANX A3 could increase the percent of cells in G2/M phase. ANX A3 was over expressed in CRC. Inhibition ANX A3 could suppress CRC cell proliferation and aggressiveness. Our study indicated that ANX A3 could be a candidate biomarker and potential therapeutic target of CRC.
What problem does this paper attempt to address?